216 related articles for article (PubMed ID: 29867214)
1. Orthosteric and allosteric action of the C5a receptor antagonists.
Liu H; Kim HR; Deepak RNVK; Wang L; Chung KY; Fan H; Wei Z; Zhang C
Nat Struct Mol Biol; 2018 Jun; 25(6):472-481. PubMed ID: 29867214
[TBL] [Abstract][Full Text] [Related]
2. Structural complexes of the agonist, inverse agonist and antagonist bound C5a receptor: insights into pharmacology and signaling.
Rana S; Sahoo AR; Majhi BK
Mol Biosyst; 2016 Apr; 12(5):1586-99. PubMed ID: 26978009
[TBL] [Abstract][Full Text] [Related]
3. Structure of the complement C5a receptor bound to the extra-helical antagonist NDT9513727.
Robertson N; Rappas M; Doré AS; Brown J; Bottegoni G; Koglin M; Cansfield J; Jazayeri A; Cooke RM; Marshall FH
Nature; 2018 Jan; 553(7686):111-114. PubMed ID: 29300009
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterisation of small molecule C5aR1 inhibitors in human cells reveals biased activities for signalling and function.
Li XX; Lee JD; Massey NL; Guan C; Robertson AAB; Clark RJ; Woodruff TM
Biochem Pharmacol; 2020 Oct; 180():114156. PubMed ID: 32682759
[TBL] [Abstract][Full Text] [Related]
5. Allosterism in human complement component 5a ((h)C5a): a damper of C5a receptor (C5aR) signaling.
Rana S; Sahoo AR; Majhi BK
J Biomol Struct Dyn; 2016 Jun; 34(6):1201-13. PubMed ID: 26212097
[TBL] [Abstract][Full Text] [Related]
6. C5aR antagonist inhibits occurrence and progression of complement C5a induced inflammatory response of microglial cells through activating p38MAPK and ERK1/2 signaling pathway.
Liu Y; Xu SQ; Long WJ; Zhang XY; Lu HL
Eur Rev Med Pharmacol Sci; 2018 Nov; 22(22):7994-8003. PubMed ID: 30536348
[TBL] [Abstract][Full Text] [Related]
7. Modeling molecular mechanisms of binding of the anaphylatoxin C5a to the C5a receptor.
Nikiforovich GV; Marshall GR; Baranski TJ
Biochemistry; 2008 Mar; 47(10):3117-30. PubMed ID: 18275159
[TBL] [Abstract][Full Text] [Related]
8. Molecular characterization of the gerbil C5a receptor and identification of a transmembrane domain V amino acid that is crucial for small molecule antagonist interaction.
Waters SM; Brodbeck RM; Steflik J; Yu J; Baltazar C; Peck AE; Severance D; Zhang LY; Currie K; Chenard BL; Hutchison AJ; Maynard G; Krause JE
J Biol Chem; 2005 Dec; 280(49):40617-23. PubMed ID: 16230349
[TBL] [Abstract][Full Text] [Related]
9. Transdermal pharmacology of small molecule cyclic C5a antagonists.
Proctor LM; Woodruff TM; Sharma P; Shiels IA; Taylor SM
Adv Exp Med Biol; 2006; 586():329-45. PubMed ID: 16893082
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of human cancer cell motility and invasiveness by anaphylatoxin C5a via aberrantly expressed C5a receptor (CD88).
Nitta H; Wada Y; Kawano Y; Murakami Y; Irie A; Taniguchi K; Kikuchi K; Yamada G; Suzuki K; Honda J; Wilson-Morifuji M; Araki N; Eto M; Baba H; Imamura T
Clin Cancer Res; 2013 Apr; 19(8):2004-13. PubMed ID: 23287562
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study.
Bekker P; Dairaghi D; Seitz L; Leleti M; Wang Y; Ertl L; Baumgart T; Shugarts S; Lohr L; Dang T; Miao S; Zeng Y; Fan P; Zhang P; Johnson D; Powers J; Jaen J; Charo I; Schall TJ
PLoS One; 2016; 11(10):e0164646. PubMed ID: 27768695
[TBL] [Abstract][Full Text] [Related]
12. The Model Structures of the Complement Component 5a Receptor (C5aR) Bound to the Native and Engineered
Sahoo AR; Mishra R; Rana S
Sci Rep; 2018 Feb; 8(1):2955. PubMed ID: 29440703
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of inflammation and fibrosis by a complement C5a receptor antagonist in DOCA-salt hypertensive rats.
Iyer A; Woodruff TM; Wu MC; Stylianou C; Reid RC; Fairlie DP; Taylor SM; Brown L
J Cardiovasc Pharmacol; 2011 Nov; 58(5):479-86. PubMed ID: 21753735
[TBL] [Abstract][Full Text] [Related]
14. Residues 10-18 within the C5a receptor N terminus compose a binding domain for chemotaxis inhibitory protein of Staphylococcus aureus.
Postma B; Kleibeuker W; Poppelier MJ; Boonstra M; Van Kessel KP; Van Strijp JA; de Haas CJ
J Biol Chem; 2005 Jan; 280(3):2020-7. PubMed ID: 15542591
[TBL] [Abstract][Full Text] [Related]
15. Complement C5a is detrimental to histological and functional locomotor recovery after spinal cord injury in mice.
Li L; Xiong ZY; Qian ZM; Zhao TZ; Feng H; Hu S; Hu R; Ke Y; Lin J
Neurobiol Dis; 2014 Jun; 66():74-82. PubMed ID: 24607885
[TBL] [Abstract][Full Text] [Related]
16. Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity.
March DR; Proctor LM; Stoermer MJ; Sbaglia R; Abbenante G; Reid RC; Woodruff TM; Wadi K; Paczkowski N; Tyndall JD; Taylor SM; Fairlie DP
Mol Pharmacol; 2004 Apr; 65(4):868-79. PubMed ID: 15044616
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of NDT 9513727 [N,N-bis(1,3-benzodioxol-5-ylmethyl)-1-butyl-2,4-diphenyl-1H-imidazole-5-methanamine], a novel, orally bioavailable C5a receptor inverse agonist.
Brodbeck RM; Cortright DN; Kieltyka AP; Yu J; Baltazar CO; Buck ME; Meade R; Maynard GD; Thurkauf A; Chien DS; Hutchison AJ; Krause JE
J Pharmacol Exp Ther; 2008 Dec; 327(3):898-909. PubMed ID: 18753409
[TBL] [Abstract][Full Text] [Related]
18. Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation.
Vergunst CE; Gerlag DM; Dinant H; Schulz L; Vinkenoog M; Smeets TJ; Sanders ME; Reedquist KA; Tak PP
Rheumatology (Oxford); 2007 Dec; 46(12):1773-8. PubMed ID: 17965442
[TBL] [Abstract][Full Text] [Related]
19. Targeting the minor pocket of C5aR for the rational design of an oral allosteric inhibitor for inflammatory and neuropathic pain relief.
Moriconi A; Cunha TM; Souza GR; Lopes AH; Cunha FQ; Carneiro VL; Pinto LG; Brandolini L; Aramini A; Bizzarri C; Bianchini G; Beccari AR; Fanton M; Bruno A; Costantino G; Bertini R; Galliera E; Locati M; Ferreira SH; Teixeira MM; Allegretti M
Proc Natl Acad Sci U S A; 2014 Nov; 111(47):16937-42. PubMed ID: 25385614
[TBL] [Abstract][Full Text] [Related]
20. Attenuation of cGVHD by C5a/C5aR blockade is associated with increased frequency of Treg.
Wang Y; Lai P; Chen X; He C; Huang X; Geng S; Luo C; Wu S; Ling W; Zhong L; Lu Z; Li P; Weng J; Du X
Sci Rep; 2017 Jun; 7(1):3603. PubMed ID: 28620195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
